Mostrar el registro sencillo del ítem
dc.contributor.author
Champion, Christophe
dc.contributor.author
Quinto, Michele Arcangelo
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Morgat, Clément
dc.contributor.author
Zanotti Fregonara, Paolo
dc.contributor.author
Hindié, Elif
dc.date.available
2018-09-27T14:22:55Z
dc.date.issued
2016-06
dc.identifier.citation
Champion, Christophe; Quinto, Michele Arcangelo; Morgat, Clément; Zanotti Fregonara, Paolo; Hindié, Elif; Comparison between three promising β-emitting radionuclides, 67Cu, 47Sc and 161Tb, with emphasis on doses delivered to minimal residual disease; Ivyspring International Publisher; Theranostics; 6; 10; 6-2016; 1611-1618
dc.identifier.issn
1838-7640
dc.identifier.uri
http://hdl.handle.net/11336/61025
dc.description.abstract
PURPOSE: Radionuclide therapy is increasingly seen as a promising option to target minimal residual disease. Copper-67, scandium-47 and terbium-161 have a medium-energy β- emission which is similar to that of lutetium-177, but offer the advantage of having diagnostic partner isotopes suitable for pretreatment imaging. The aim of this study was to compare the efficacy of 67Cu, 47Sc and 161Tb to irradiate small tumors. METHODS: The absorbed dose deriving from a homogeneous distribution of 67Cu, 47Sc or 161Tb in water-density spheres was calculated with the Monte Carlo code CELLDOSE. The diameters of the spheres ranged from 5 mm to 10 μm, thus simulating micrometastases or single tumor cells. All electron emissions, including β- spectra, Auger and conversion electrons were taken into account. Because these radionuclides differ in electron energy per decay, the simulations were run assuming that 1 MeV was released per μm3, which would result in a dose of 160 Gy if totally absorbed. RESULTS: The absorbed dose was similar for the three radionuclides in the 5-mm sphere (146-149 Gy), but decreased differently in smaller spheres. In particular, 161Tb delivered higher doses compared to the other radionuclides. For instance, in the 100-μm sphere, the absorbed dose was 24.1 Gy with 67Cu, 14.8 Gy with 47Sc and 44.5 Gy with 161Tb. Auger and conversion electrons accounted for 71% of 161Tb dose. The largest dose differences were found in cell-sized spheres. In the 10-μm sphere, the dose delivered by 161Tb was 4.1 times higher than that from 67Cu and 8.1 times that from 47Sc. CONCLUSION: 161Tb can effectively irradiate small tumors thanks to its decay spectrum that combines medium-energy β- emission and low-energy conversion and Auger electrons. Therefore 161Tb might be a better candidate than 67Cu and 47Sc for treating minimal residual disease in a clinical setting.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Ivyspring International Publisher
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Copper-67
dc.subject
Dose
dc.subject
Lutetium-177
dc.subject
Micrometastases
dc.subject
Minimal Residual Disease
dc.subject
Radionuclide Therapy
dc.subject
Scandium-47
dc.subject
Terbium-161
dc.subject.classification
Medicina Critica y de Emergencia
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Comparison between three promising β-emitting radionuclides, 67Cu, 47Sc and 161Tb, with emphasis on doses delivered to minimal residual disease
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2018-09-26T13:49:41Z
dc.journal.volume
6
dc.journal.number
10
dc.journal.pagination
1611-1618
dc.journal.pais
Australia
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Wyoming
dc.description.fil
Fil: Champion, Christophe. Centre National de la Recherche Scientifique; Francia. Universite de Bordeaux; Francia
dc.description.fil
Fil: Quinto, Michele Arcangelo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centre National de la Recherche Scientifique; Francia. Universite de Bordeaux; Francia
dc.description.fil
Fil: Morgat, Clément. Universite de Bordeaux; Francia
dc.description.fil
Fil: Zanotti Fregonara, Paolo. Universite de Bordeaux; Francia
dc.description.fil
Fil: Hindié, Elif. Universite de Bordeaux; Francia
dc.journal.title
Theranostics
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://dx.doi.org/10.7150/thno.15132
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://www.thno.org/v06p1611.htm
Archivos asociados